Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Accelerant Holdings Co-Founder, Chief U/W Officer Francis James O’Neill reports ARX share disposal worth $3.15 million

Accelerant Holdings Co-Founder, Chief U/W Officer Francis James O’Neill reports ARX share disposal worth $3.15 million

ReutersReuters2026/07/29 22:26
  • Accelerant Holdings Co-Founder, Chief U/W Officer Francis James O’Neill disclosed sales of 215,114 Class A common shares on July 27-28.
  • Shares were sold at weighted average prices of $14.63 and $14.56.
  • Indirect stake held via Famed Ventures Limited fell to 6,522,125 Class A common shares.
  • O’Neill also reported 166,644 Class A common shares held directly following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerant Holdings published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-050691), on July 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma